MarkusYMaparaMDPhD

PubMed

• 1 citations
  Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis.
  Abdul-Hamid Bazarbachi, Divaya Bhutani, Jai Radhakrishnan, Markus Mapara, Mathew S Maurer
  American Journal of Hematology. 2024-11-01
• 1 citations
  Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.
  Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek H Mouhieddine, Juan Esteban Velez-Hernandez
  Blood Advances. 2024-08-13
• High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy.
  George S Mellgard, Divaya Bhutani, Markus Y Mapara, Mathew S Maurer, Jai Radhakrishnan
  Bone Marrow Transplantation. 2024-08-01

Journal Articles

• Immunomodulatory Drugs Downregulate IKZF1 Leading to Expansion of Hematopoietic Progenitors with Concomitant Block of Megakaryocytic Maturation  
  Markus Y Mapara, Sara A Monaghan, Suzanne Lentzsch, Haematologica
• Brentuximab Vedotin and Bendamustine Produce High Complete Response Rates in Patients with Chemotherapy Refractory Hodgkin Lymphoma  
  Changchun Deng, Markus Y. Mapara, Ahmed Sawas, Matko Kalac, British Journal of Haematology

Abstracts/Posters

• Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Pha...
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: ...
  Markus Y Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations
  Markus Y Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018